{
  "quoteSummary": {
    "result": [
      {
        "defaultKeyStatistics": {
          "maxAge": 1,
          "priceHint": {
            "raw": 2,
            "fmt": "2",
            "longFmt": "2"
          },
          "enterpriseValue": {
            "raw": 557815680,
            "fmt": "557.82M",
            "longFmt": "557,815,680"
          },
          "forwardPE": {},
          "profitMargins": {
            "raw": 0.019340001,
            "fmt": "1.93%"
          },
          "floatShares": {
            "raw": 54825362,
            "fmt": "54.83M",
            "longFmt": "54,825,362"
          },
          "sharesOutstanding": {
            "raw": 126503000,
            "fmt": "126.5M",
            "longFmt": "126,503,000"
          },
          "sharesShort": {},
          "sharesShortPriorMonth": {},
          "heldPercentInsiders": {},
          "heldPercentInstitutions": {},
          "shortRatio": {},
          "shortPercentOfFloat": {},
          "beta": {
            "raw": -1.631343,
            "fmt": "-1.63"
          },
          "morningStarOverallRating": {},
          "morningStarRiskRating": {},
          "category": null,
          "bookValue": {
            "raw": 2.515,
            "fmt": "2.52"
          },
          "priceToBook": {
            "raw": 1.5546719,
            "fmt": "1.55"
          },
          "annualReportExpenseRatio": {},
          "ytdReturn": {},
          "beta3Year": {},
          "totalAssets": {},
          "yield": {},
          "fundFamily": null,
          "fundInceptionDate": {},
          "legalType": null,
          "threeYearAverageReturn": {},
          "fiveYearAverageReturn": {},
          "priceToSalesTrailing12Months": {},
          "lastFiscalYearEnd": {
            "raw": 1490918400,
            "fmt": "2017-03-31"
          },
          "nextFiscalYearEnd": {
            "raw": 1553990400,
            "fmt": "2019-03-31"
          },
          "mostRecentQuarter": {
            "raw": 1514678400,
            "fmt": "2017-12-31"
          },
          "earningsQuarterlyGrowth": {
            "raw": -0.687,
            "fmt": "-68.70%"
          },
          "revenueQuarterlyGrowth": {},
          "netIncomeToCommon": {
            "raw": 8293250,
            "fmt": "8.29M",
            "longFmt": "8,293,250"
          },
          "trailingEps": {
            "raw": 0.066,
            "fmt": "0.07"
          },
          "forwardEps": {},
          "pegRatio": {},
          "lastSplitFactor": "10/1",
          "lastSplitDate": {
            "raw": 1260748800,
            "fmt": "2009-12-14"
          },
          "enterpriseToRevenue": {
            "raw": 1.301,
            "fmt": "1.30"
          },
          "enterpriseToEbitda": {
            "raw": 18.408,
            "fmt": "18.41"
          },
          "52WeekChange": {
            "raw": -0.3288591,
            "fmt": "-32.89%"
          },
          "SandP52WeekChange": {
            "raw": 0.12668931,
            "fmt": "12.67%"
          },
          "lastDividendValue": {},
          "lastCapGain": {},
          "annualHoldingsTurnover": {}
        },
        "summaryProfile": {
          "address1": "Plot No. 144, Akash Ganga",
          "address2": "3rd Floor Srinagar Colony",
          "city": "Hyderabad",
          "zip": "500073",
          "country": "India",
          "phone": "91 40 6733 4400",
          "fax": "91 40 6733 4401",
          "website": "http://www.gennexlab.com",
          "industry": "Drugs - Generic",
          "sector": "Healthcare",
          "longBusinessSummary": "Gennex Laboratories Limited manufactures and sells bulk drugs and intermediates in India and internationally. It offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol, a non-narcotic and non-toxic drug used in treating conditions, such as spasm and pain associated with acute musculoskeletal disorders, tension, myalgia, acute traumatic muscle spasm, acute disc prolapse, painful shoulder syndrome, etc.; and Phenazopyridine Hydrochloride, a drug that has analgesic effect in the urinary tract and gives symptomatic relief of dysuria. The company also provides Fluconazole, a bis-triazole anti-fungal drug used for the treatment of fungal infections; Metformin Hcl, a non-insulin anti-diabetic; Ambroxol Hcl, a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus; and Melitracen Hydrochloride, a tricyclic antidepressant. In addition, it is involved in the development of active pharmaceuticals ingredients, such as Flupentixol DIHCL BP, Domperidone BP/EP, Mephenesin BP, Mefanemic Acid USP/BP/IP, and Chlorophenesin USP/BP. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.",
          "fullTimeEmployees": 91,
          "companyOfficers": [],
          "maxAge": 86400
        },
        "financialData": {
          "maxAge": 86400,
          "currentPrice": {
            "raw": 3.91,
            "fmt": "3.91"
          },
          "targetHighPrice": {},
          "targetLowPrice": {},
          "targetMeanPrice": {},
          "targetMedianPrice": {},
          "recommendationMean": {},
          "recommendationKey": "none",
          "numberOfAnalystOpinions": {},
          "totalCash": {
            "raw": 6935000,
            "fmt": "6.93M",
            "longFmt": "6,935,000"
          },
          "totalCashPerShare": {
            "raw": 0.054,
            "fmt": "0.05"
          },
          "ebitda": {
            "raw": 30303520,
            "fmt": "30.3M",
            "longFmt": "30,303,520"
          },
          "totalDebt": {
            "raw": 22129000,
            "fmt": "22.13M",
            "longFmt": "22,129,000"
          },
          "quickRatio": {},
          "currentRatio": {},
          "totalRevenue": {
            "raw": 428766208,
            "fmt": "428.77M",
            "longFmt": "428,766,208"
          },
          "debtToEquity": {
            "raw": 6.983,
            "fmt": "6.98"
          },
          "revenuePerShare": {
            "raw": 3.4,
            "fmt": "3.40"
          },
          "returnOnAssets": {},
          "returnOnEquity": {},
          "grossProfits": {
            "raw": 142018577,
            "fmt": "142.02M",
            "longFmt": "142,018,577"
          },
          "freeCashflow": {},
          "operatingCashflow": {},
          "earningsGrowth": {
            "raw": -0.692,
            "fmt": "-69.20%"
          },
          "revenueGrowth": {
            "raw": 0.239,
            "fmt": "23.90%"
          },
          "grossMargins": {
            "raw": 0.32519,
            "fmt": "32.52%"
          },
          "ebitdaMargins": {
            "raw": 0.07068,
            "fmt": "7.07%"
          },
          "operatingMargins": {
            "raw": 0.05104,
            "fmt": "5.10%"
          },
          "profitMargins": {
            "raw": 0.019340001,
            "fmt": "1.93%"
          },
          "financialCurrency": "INR"
        }
      }
    ],
    "error": null
  }
}